Pictet Asset Management Holding SA cut its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 346,617 shares of the company's stock after selling 10,219 shares during the period. Pictet Asset Management Holding SA owned about 0.54% of MoonLake Immunotherapeutics worth $18,769,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its holdings in shares of MoonLake Immunotherapeutics by 3.4% in the third quarter. The Manufacturers Life Insurance Company now owns 118,126 shares of the company's stock worth $5,956,000 after buying an additional 3,892 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in MoonLake Immunotherapeutics by 96.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,814 shares of the company's stock valued at $1,806,000 after acquiring an additional 17,580 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in MoonLake Immunotherapeutics in the 3rd quarter worth $741,000. HighVista Strategies LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 3.1% during the 3rd quarter. HighVista Strategies LLC now owns 43,541 shares of the company's stock valued at $2,195,000 after purchasing an additional 1,292 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its position in shares of MoonLake Immunotherapeutics by 1.6% during the third quarter. Parkman Healthcare Partners LLC now owns 102,813 shares of the company's stock valued at $5,184,000 after purchasing an additional 1,589 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company's stock.
MoonLake Immunotherapeutics Trading Down 2.2 %
Shares of NASDAQ MLTX traded down $0.85 during trading hours on Friday, hitting $37.21. 484,875 shares of the company traded hands, compared to its average volume of 341,050. The company's 50 day moving average price is $41.36 and its 200 day moving average price is $47.31. MoonLake Immunotherapeutics has a 12 month low of $35.39 and a 12 month high of $58.26. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of -28.84 and a beta of 1.32.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09). Equities analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.
Analyst Ratings Changes
A number of research firms recently commented on MLTX. Royal Bank of Canada started coverage on MoonLake Immunotherapeutics in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $67.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Needham & Company LLC increased their target price on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group reduced their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $80.50.
Check Out Our Latest Analysis on MLTX
MoonLake Immunotherapeutics Company Profile
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
See Also
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
